On Tuesday, July 16, Welldoc’s Chief Strategy Officer held a webinar with the Digital Therapeutic Alliance’s Megan Coder. It kicked off a series of webinars Welldoc will be hosting on the value of digital therapeutics and key lessons learned from some of the pioneers and innovators in the space. Let’s dig in with five key takeaways.
Number One: Digital therapeutics are here to make positive changes
According to the Digital Therapeutics Alliance, the definition of a digital therapeutic is:
“Digital therapeutics deliver evidence-based therapeutic interventions to patients and providers to prevent, manage, or treat a medical disease or disorder”
Overall, these are tools which play a unique role in broader delivery of care. A number of tools can co-exist with digital therapeutics, including telehealth, mobile health, health information technology (HIT), devices or wearables, and personalized healthcare.
Number Two: Technology born from a necessity to support patients
The digital therapeutics industry is born from a series of convergent forces, which includes, among other factors, the rising incidence and cost of chronic conditions. Technology is moving incredibly fast – be it in devices, apps, integration, sensors, wearables, etc.
In many ways with digital therapeutics, the active and often missing ingredient is patient engagement, which when combined with innovation, clinical oversight and the right, clinically-validated and proven tools, help solve the outcomes and cost conundrum by engaging patients in meaningful ways that may not be addressed by drugs alone.
Number Three: Not just hardware or software. It’s design, usability, and security, too
DTx products incorporate advanced technology best practices relating to design, clinical evaluation, usability, and data security.
Digital therapeutics empower patients, clinicians, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Number Four: Required to work with regulatory bodies
Organizations making digital therapeutics are reviewed and cleared or approved by regulatory bodies as required to support product claims of risk, efficacy, and intended use. They also make claims appropriate to clinical validation and regulatory status. And work to publish trial results with meaningful outcomes in peer-reviewed journals.
Number Five: Digital health is a category, digital therapeutics are a specialty.
For years, organizations have been hearing about digital health. Whether that’s a new fitness app, or a new diet with digital support. What sets these digital health apps apart from digital therapeutics is the rigor by which they’re developed, validated, deployed and supported regulatory and clinical efficacy, and proven results.
Digital therapeutics have a basis in science, are rigorously tested, and designed for humans with advanced technology.
Watch the recorded webinar here.